About this trial
The overall goals of this proposal are to determine the genetic architecture of recurrent pregnancy loss (RPL) and to discover genomic predictors of RPL.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Women with loss of a current singleton pregnancy at < 20 0/7 weeks gestation, documented by ultrasonography or histopathological examination
History of one or more prior pregnancy losses
Euploid current pregnancy confirmed by karyotype, microarray, or STORK (Short-read Transpore Rapid Karyotyping) sequencing Note: A limited number of aneuploid losses will be included as part of the pilot phase
Disqualifiers
History of parental karyotype abnormalities
History of antiphospholipid antibody syndrome
Evidence of uncontrolled diabetes
Evidence of uncontrolled thyroid disease
Trial population
Couples who have had two or more previous pregnancy losses and have undiagnosed cause of recurrent pregnancy loss.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Determine genetic etiology for Recurrent Pregnancy Loss
The WGS tool will be used to analyze the POC sample and parental blood samples to determine the clinical reportable genetic cause for RPL
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Yale University
Lead sponsor
Johns Hopkins University
Collaborator
University of Texas at Austin
Collaborator
Penn State University
Collaborator
Northwestern University
Collaborator
The University of Texas Health Science Center at San Antonio
Collaborator
Wayne State University
Collaborator
Columbia University
Collaborator
University of Colorado, Denver
Collaborator
University of Chicago
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
University of Utah
Collaborator